Sign in to view content

Modeling the Effect of Longer-Acting Drugs and Reimbursement Changes

Robert A Diamond, BBA

Video
Published 2022

Related

Ixoberogene Soroparvovec (Ixo-vec) IVT Gene Therapy for Neovascular AMD: First Time 26-Week Interim Analysis Results from the Phase 2 LUNA Study
Charles C Wykoff, MD, PhD, FASRS
Updates from the Field
2024
Endophthalmitis After Intravitreal Injections with 0.05% Aqueous Chlorhexidine vs 5% Povidone-Iodine as Ocular Antiseptics
Murtaza K Adam, MD
Annual Meeting Talks
2022
Brolucizumab for the treatment of visual impairment due to diabetic macular edema: 52-week results from the KITE and KESTREL studies
David M. Brown, MD
Updates from the Field
2021

Category: Practice Management

Anti VEGF

See more